Willow Biosciences Valuation
| WLLW Stock | CAD 0.07 0.01 6.25% |
Willow Biosciences seems to be overvalued based on Macroaxis valuation methodology. Our model calculates the value of Willow Biosciences from examining the company fundamentals such as Shares Outstanding of 144.2 M, operating margin of (1.41) %, and Return On Asset of -0.75 as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Willow Biosciences' valuation include:
Price Book 59.1607 | Enterprise Value 12.4 M | Enterprise Value Ebitda (332.50) | Price Sales 6.2697 | Forward PE 67.5676 |
Overvalued
Today
Please note that Willow Biosciences' price fluctuation is out of control at this time. Calculation of the real value of Willow Biosciences is based on 3 months time horizon. Increasing Willow Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Willow Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Willow Stock. However, Willow Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.075 | Real 0.0714 | Hype 0.08 |
The intrinsic value of Willow Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Willow Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Willow Biosciences helps investors to forecast how Willow stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Willow Biosciences more accurately as focusing exclusively on Willow Biosciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Willow Biosciences' intrinsic value based on its ongoing forecasts of Willow Biosciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Willow Biosciences' closest peers.
Willow Biosciences Cash |
|
Willow Valuation Trend
Knowing Willow Biosciences' actual value is paramount for traders when making sound investment determinations. Using both Willow Biosciences' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Willow Biosciences Total Value Analysis
Willow Biosciences is at this time estimated to have takeover price of 12.44 M with market capitalization of 11.54 M, debt of 2.16 M, and cash on hands of 11.01 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Willow Biosciences fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
12.44 M | 11.54 M | 2.16 M | 11.01 M |
Willow Biosciences Investor Information
About 24.0% of the company outstanding shares are owned by insiders. The company recorded a loss per share of 0.05. Willow Biosciences last dividend was issued on the 27th of March 2017. The entity had 1:25 split on the 21st of May 2019. Based on the key indicators related to Willow Biosciences' liquidity, profitability, solvency, and operating efficiency, Willow Biosciences is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Willow Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Willow Biosciences has an asset utilization ratio of 17.56 percent. This suggests that the Company is making C$0.18 for each dollar of assets. An increasing asset utilization means that Willow Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.Willow Biosciences Ownership Allocation
Willow Biosciences retains a total of 144.2 Million outstanding shares. Willow Biosciences owns significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.Willow Biosciences Profitability Analysis
The company reported the revenue of 1.17 M. Net Loss for the year was (13.03 M) with profit before overhead, payroll, taxes, and interest of 821 K.About Willow Biosciences Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Willow Biosciences. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Willow Biosciences based exclusively on its fundamental and basic technical indicators. By analyzing Willow Biosciences's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Willow Biosciences's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Willow Biosciences. We calculate exposure to Willow Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Willow Biosciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -659 K | -692 K | |
| Pretax Profit Margin | (11.12) | (11.68) | |
| Operating Profit Margin | (11.25) | (11.81) | |
| Net Loss | (11.12) | (11.67) | |
| Gross Profit Margin | (0.56) | (0.59) |
Other Information on Investing in Willow Stock
Willow Biosciences financial ratios help investors to determine whether Willow Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Willow with respect to the benefits of owning Willow Biosciences security.